Condition: Elevated LDL-C and High Cholesterol · Sponsor: Monash University
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene. STX-1150 comprises an mRNA and guide RNA (gRNA) delivered via lipid nanoparticles (LNP) for intravenous infusion. The mRNA produces a protein that switches off the PCSK9 gene expression without altering the DNA sequence. This process leverages natural mechanisms that regulate gene activity. The study will enroll up to 64 participants with elevated LDL-C across sites in Australia and New Zealand. The follow-up period will be up to 1- year post-treatment.
This description comes directly from the study's public registry record.
Domenic Sacca · +61 423245187 · domenic.sacca@monash.edu
Raeda Mustafa · +61 477581540 · raeda.mustafa@monash.edu
Always discuss trial participation with your own doctor first.
| Monash Health/ Victorian Heart Hospital (VHH) | Clayton, Victoria, Australia | Recruiting |
| New Zealand Clinical Research (NZCR) | Christchurch, Christchurch, New Zealand | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07428473